Dynavax Technologies
Dynavax Technologies is a biopharmaceutical company discovering and developing novel products to prevent and treat infectious diseases.
About Dynavax Technologies
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018TM adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza.
Company Facts
- Headquarters
- Berkeley
- Founded
- 1996
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- public
- Employees
- c_00251_00500
- Funding Stage
- m_and_a
- Total Funding
- $1,579,500,000
- Last Funding Type
- post_ipo_debt
- Last Funding Date
- 2025-03-06
- Website
- dynavax.com
Industries & Categories
Biopharma, Biotechnology, Clinical Trials, Health Care, Medical Device
Social Links
Canonical: https://fsome.com/organization/dynavax-technologies-15250 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.